Showing 2941-2950 of 6036 results for "".
- Tarsus Releases Data from Io and Europa Trials for TP-03 to Treat Demodex Blepharitis and Begins Phase 2b/3 Saturn-1 Trialhttps://modernod.com/news/tarsus-releases-data-from-io-and-europa-trials-for-tp-03-to-treat-demodex-blepharitis-and-begins-phase-2b-3-saturn-1-trial/2478374/Tarsus Pharmaceuticals announced data from its phase 2 trials, Io (a Phase 2a, single-arm open-label trial) and Europa (a Phase 2b, randomized vehicle-controlled trial), evaluating the safety and efficacy of TP-03, a novel ophthalmic therapeutic being developed for t
- Contact Lens Institute Announces The EASY Way Program to Simplify Contact Lens Wear & Carehttps://modernod.com/news/contact-lens-institute-announces-the-easy-way-program-to-simplify-contact-lens-wear-care/2478377/To generate greater consumer familiarity with contact lens health and safety year-round in the United States and Canada, the Contact Lens Institute (CLI) has launched “The EASY Way” (Eyes, Awareness, Safety and You). The program includes simplified
- New Phase 3 Analysis Demonstrates Beovu Showed Improvement in BCVA in Wet AMD Patients With Early Persistent Fluidhttps://modernod.com/news/new-phase-3-analysis-demonstrates-beovu-showed-improvement-in-bcva-in-wet-amd-patients-with-early-persistent-fluid/2478364/Novartis announced that results of two new post-hoc analyses of the phase 3 HAWK and HARRIER clinical trials in wet age-related macular degeneration (AMD) were presented at the Euretina 2020 virtual congress. The first analysis demonstrated fewer Beovu (brolucizumab) patients had early per
- Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosahttps://modernod.com/news/eyevensys-receives-fda-orphan-drug-designation-for-eys611-for-treatment-of-retinitis-pigmentosa/2478365/Eyevensys announced that the FDA has granted an orphan-drug designation for EYS611 for the treatment of retinitis pigmentosa (RP). Eyevensys is developing EYS611, a DNA plasmid that encodes for the human transferrin protein, to benefit patients diagnosed with RP, as well as other degenerat
- Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopiahttps://modernod.com/news/orasis-raises-30-million-to-advance-the-clinical-development-of-novel-treatment-for-presbyopia/2478356/Orasis Pharmaceuticals announced the closing of a $30 million Series C financing. Proceeds from the financing will be used to advance Orasis’ lead eye drop candidate for the treatment of presbyopia sympto
- iSTAR Medical Reports Positive 6-Month Data for MINIject Devicehttps://modernod.com/news/istar-medical-reports-positive-6-month-data-for-miniject-device/2478354/iSTAR Medical announced that its microinvasive glaucoma surgery (MIGS) device MINIject showed consistently positive safety and efficacy outcomes in a larger patient population from ongoing trials. The pooled analysis reviewed data from over 130 patients implanted with MINIject into the supracilia
- Study: Essilor’s Stellest Lens Slows Down Myopia Progression in Children by More Than 60% After One Yearhttps://modernod.com/news/study-essilors-stellest-lens-slows-down-myopia-progression-in-children-by-more-than-60-after-one-year/2478339/Essilor reported that after 1 year of an ongoing clinical trial, there was a more than 60% slowdown in myopia progression in children on average with the recently launched Stellest lens, compared to a single vision lenses. Essilor launched the Stellest lens in the Wenzhou Medical Universit
- Fauci Offers Defense of Why Americans Can Trust the Approval Process for a Potential COVID-19 Vaccinehttps://modernod.com/news/fauci-offers-defense-of-why-americans-can-trust-the-approval-process-for-a-potential-covid-19-vaccine/2478314/A potential COVID-19 vaccine is likely to approved in November or December, but the announcement of any such vaccine will not be based in any way on a political timeline, infectious disease expert Anthony Fauci, MD, said Tuesday evening during The Atlantic Festival, according to a FierceHealthcar
- Gyroscope Therapeutics Granted FDA Fast Track Designation for Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-granted-fda-fast-track-designation-for-investigational-gene-therapy-for-dry-amd/2478305/Gyroscope Therapeutics announced that the FDA has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is an investigational one-time AAV-based gene therapy that is delivered under the retina and is i
- CooperVision Recaps Complimentary Contact Lens Program for Essential Hospital Workershttps://modernod.com/news/coopervision-recaps-complimentary-contact-lens-program-for-essential-hospital-workers/2478307/Over the past 4 months, CooperVision’s Essential Hospital Workers Complimentary Contact Lens Program enabled eye care professionals to provide support to patients working on the front lines of the COVID-19 pandemic. By the program’s conclusion on August 31, nearly 570 optometry practices from 46